Rofstad Einar K, Mathiesen Berit, Henriksen Kristin, Kindem Kristil, Galappathi Kanthi
Group of Radiation Biology and Tumor Physiology, Department of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Montebello, Oslo, Norway.
Cancer Res. 2005 Mar 15;65(6):2387-96. doi: 10.1158/0008-5472.CAN-04-3039.
Cancer patients with recurrent local disease after radiation therapy have increased probability of developing regional and distant metastases. The mechanisms behind this observation were studied in the present work by using D-12 and R-18 human melanoma xenografts growing in preirradiated beds in BALB/c-nu/nu mice as preclinical models of recurrent primary tumors in humans. D-12 tumors metastasize to the lungs, whereas R-18 tumors develop lymph node metastases. Based on earlier studies, we hypothesized that metastasis was governed primarily by the proangiogenic factor interleukin-8 (IL-8) in D-12 tumors and by the invasive growth-promoting receptor urokinase-type plasminogen activator receptor (uPAR) in R-18 tumors. Pimonidazole was used as a hypoxia marker, and hypoxia, microvascular hotspots, and the expression of IL-8 and uPAR were studied by immunohistochemistry. The metastatic frequency was significantly higher in tumors in preirradiated beds than in control tumors in unirradiated beds, and it increased with the preirradiation dose. D-12 tumors showed increased fraction of hypoxic cells, increased fraction of IL-8-positive cells, and increased density of microvascular hotspots in preirradiated beds, and R-18 tumors showed increased fraction of hypoxic cells and increased fraction of uPAR-positive cells in preirradiated beds. Strong correlations were found between these parameters and metastatic frequency. IL-8 was up-regulated in hypoxic regions of D-12 tumors, and uPAR was up-regulated in hypoxic regions of R-18 tumors. Daily treatment with anti-IL-8 antibody (D-12) or anti-uPAR antibody (R-18) suppressed metastasis significantly. Our preclinical study suggests that primary tumors recurring after inadequate radiation therapy may show increased metastatic propensity because of increased fraction of hypoxic cells and hypoxia-induced up-regulation of metastasis-promoting gene products. Two possible mechanisms were identified: hypoxia may enhance metastasis by inducing neoangiogenesis facilitating hematogenous spread and by promoting invasive growth facilitating lymphogenous spread. The aggressive behavior of postirradiation local recurrences suggests that they should be subjected to curative treatment as early as possible to prevent further metastatic dissemination. Moreover, the possibility that patients with a high probability of developing local recurrences after radiation therapy may benefit from postirradiation treatment with antiangiogenic and/or anti-invasive agents merits clinical investigation.
放疗后出现局部疾病复发的癌症患者发生区域和远处转移的可能性增加。在本研究中,我们以生长于BALB/c-nu/nu小鼠预先照射部位的D-12和R-18人黑色素瘤异种移植瘤作为人类复发性原发性肿瘤的临床前模型,研究了这一现象背后的机制。D-12肿瘤转移至肺部,而R-18肿瘤发生淋巴结转移。基于早期研究,我们推测,D-12肿瘤的转移主要由促血管生成因子白细胞介素-8(IL-8)调控,而R-18肿瘤的转移则由促进侵袭性生长的受体尿激酶型纤溶酶原激活物受体(uPAR)调控。使用匹莫硝唑作为缺氧标志物,通过免疫组织化学研究缺氧、微血管热点以及IL-8和uPAR的表达。预先照射部位肿瘤的转移频率显著高于未照射部位的对照肿瘤,且随着预先照射剂量的增加而升高。D-12肿瘤在预先照射部位显示缺氧细胞比例增加、IL-8阳性细胞比例增加以及微血管热点密度增加,而R-18肿瘤在预先照射部位显示缺氧细胞比例增加和uPAR阳性细胞比例增加。这些参数与转移频率之间存在强相关性。在D-12肿瘤的缺氧区域IL-8上调,在R-18肿瘤的缺氧区域uPAR上调。每日用抗IL-8抗体(D-12)或抗uPAR抗体(R-18)治疗可显著抑制转移。我们的临床前研究表明,放疗不足后复发的原发性肿瘤可能因缺氧细胞比例增加以及缺氧诱导的促转移基因产物上调而表现出更高的转移倾向。确定了两种可能的机制:缺氧可能通过诱导新生血管生成促进血行播散以及通过促进侵袭性生长促进淋巴道播散来增强转移。放疗后局部复发的侵袭性行为表明,应尽早对其进行根治性治疗以防止进一步的转移扩散。此外,放疗后发生局部复发可能性高的患者可能从抗血管生成和/或抗侵袭药物的放疗后治疗中获益,这一可能性值得临床研究。